sample text for news, o nanoCelex platform covers target discovery to identification of lead antimicrobial antibody fragments. The lead protein targets from various pathogens are identified through extensive bioinformatics and biochemical analyses and used for screening our nanoCelex antibody fragment libraries in vitro. Screening of the library will be done for multiple rounds and by applying desired selective pressure at each round to ultimately develop the optimal binding variants with desired features, e.g. resistance against heat and proteases. The optimized sequence will be further engineered for expression in appropriate expression systems and produced at commercial scale for various applications. Our infrastructure, expertise and access to large collections of well-defined environmental or clinical samples, will make AbCelex an excellent partner for discovery, development and commercialization of new diagnostic assays and devices.